Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease-Authors' reply.

Saved in:
Bibliographic Details
Title: Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease-Authors' reply.
Authors: Yiu TH; School of Public Health, University of Sydney, Sydney, New South Wales, Australia., Ko Y; School of Medicine, Western Sydney University, Sydney, New South Wales, Australia.; Gastrointestinal and Liver Services Research Unit, Concord Repatriation General Hospital, Sydney, New South Wales, Australia., Pudipeddi A; Gastrointestinal and Liver Services Research Unit, Concord Repatriation General Hospital, Sydney, New South Wales, Australia., Natale P; School of Public Health, University of Sydney, Sydney, New South Wales, Australia.; Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J), University of Bari Aldo Moro, Bari, Italy.; Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy., Leong RW; Gastrointestinal and Liver Services Research Unit, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
Source: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2024 Jul; Vol. 60 (1), pp. 103-104. Date of Electronic Publication: 2024 May 23.
Publication Type: Letter; Comment
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1365-2036
DOI:10.1111/apt.18057